COVID-19 Infection Carries Higher Myocarditis Risk Than Vaccine
The risk of developing myocarditis after a natural SARS-CoV-2 infection is nearly five times higher than following an mRNA-based vaccination, according to a cohort study published in the journal Vaccine. Biermann-Medizin reported that while rare cases of heart muscle inflammation following COVID-19 immunization contributed to public vaccine hesitancy among adolescents and young adults, recent comprehensive data point to a much more favorable risk profile for the vaccine than for the virus itself.
- Researchers analyzed TriNetX network data covering over four million individuals aged 16 to 25 between December 2020 and September 2025.
- Documentation showed that the BNT162b2 mRNA vaccine reduced the risk of myocarditis by 85 percent compared to a documented viral infection.
- The absolute risk difference for myocarditis equaled one fewer case per 2,827 vaccinated individuals relative to those infected.
Cohort Analysis of Four Million Patients
Eman A. Toraih and colleagues at the SUNY Upstate Medical University in Syracuse, USA, examined retrospective data from the TriNetX platform to clarify cardiac risks in younger populations. The study captured 4,072,375 participants between the ages of 16 and 25. Investigators stratified the cohort by immune status into four distinct categories: uninfected and unvaccinated numbering 3,572,000, infected and unvaccinated totaling 248,546, uninfected and vaccinated comprising 241,152, and those both infected and vaccinated at 10,677. Using propensity-score matching, the research team evaluated six-month clinical events across these groups to isolate the specific cardiac consequences of immunization versus wild-type infection.
Infected and Unvaccinated Cohort Faced Highest Myocarditis Incidence
The highest cumulative incidence of myocarditis occurred in the infected and unvaccinated cohort at 0.116 percent. Relative risk calculations demonstrated that contracting SARS-CoV-2 without prior immunization elevated the likelihood of myocarditis to an RR of 4.91 with a 95 percent confidence interval ranging from 3.11 to 7.77. Perikarditis risks also rose under infection, showing an RR of 1.93, alongside a mortality risk increase yielding an RR of 1.33. Conversely, receiving the BNT162b2 vaccine provided substantial relative risk reductions when placed directly against a documented viral infection. The vaccine lowered myocarditis incidence by 85 percent, reduced pericarditis by 79 percent, and decreased overall mortality by 72 percent.
Interpretation of Observational Findings
Study authors concluded that these metrics support a favorable benefit-risk ratio for the BNT162b2 vaccine among adolescents and young adults when weighed against the cardiac and mortality hazards associated with the virus. Investigators noted, however, that overall mortality comparisons derived from observational datasets require cautious interpretation as descriptive rather than strictly causal.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.